Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone

S. M. Jafri, S. Borzak, Jeffrey Goldberger, M. Gheorghiade

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalProgress in Cardiovascular Diseases
Volume41
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Amiodarone
Myocardial Infarction
Cardiac Arrhythmias
Mortality
Sudden Death
Therapeutics
Clinical Trials
Survival
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. / Jafri, S. M.; Borzak, S.; Goldberger, Jeffrey; Gheorghiade, M.

In: Progress in Cardiovascular Diseases, Vol. 41, No. 1, 01.01.1998, p. 65-70.

Research output: Contribution to journalReview article

@article{143d4b39fdec4cecab9192329ec5e385,
title = "Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone",
abstract = "The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.",
author = "Jafri, {S. M.} and S. Borzak and Jeffrey Goldberger and M. Gheorghiade",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0033-0620(98)80023-6",
language = "English (US)",
volume = "41",
pages = "65--70",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone

AU - Jafri, S. M.

AU - Borzak, S.

AU - Goldberger, Jeffrey

AU - Gheorghiade, M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.

AB - The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.

UR - http://www.scopus.com/inward/record.url?scp=0031880762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031880762&partnerID=8YFLogxK

U2 - 10.1016/S0033-0620(98)80023-6

DO - 10.1016/S0033-0620(98)80023-6

M3 - Review article

C2 - 9717860

AN - SCOPUS:0031880762

VL - 41

SP - 65

EP - 70

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 1

ER -